Project Grant K08AI182478
Award Date
8/1/24
Completion Date
6/30/29
Dollars Obligated
$196K
Federal Agency
National Institute of Allergy and Infectious Diseases
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
St. Louis, MO 63110, USA
Similar Awards
This federal Project Grant award of $479,249, provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to study the molecular mechanisms regulating neutrophil proinflammatory activity in sepsis. The key objectives are to: Determine the molecular basis of neutrophil A20 signaling in regulating neutrophil proinflammatory function under septic conditions. Utilize two-photon intravital...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $226,253 to The Washington University in St. Louis to conduct research on modulating neutrophil-endothelial interactions by the ADAM10 protein in the context of Staphylococcus aureus infections. The goal is to generate a spatiotemporal analysis of the interaction between neutrophils and the endothelium during the early...
This $186,221 Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) supports research to develop personalized sepsis therapies for pediatric patients. The key objectives are to: Augment sepsis phenotypes by incorporating high-frequency physiological data to identify additional subtypes and predict disease progression. Retrospectively develop and externally validate predictive algorithms to identify...
This Project Grant award of $190,058 from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) aims to define the role of the protein ADAM9 in the immune response to SARS-CoV-2 infection and its impact on lung injury in severe COVID-19 cases. The research will be conducted at the University of Massachusetts Medical School and builds on the candidate's previous work on the ADAM9/MDA5 innate immune pathway. The findings are expected...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $424,223 Project Grant under the Allergy and Infectious Diseases Research (CFDA 93.855) program to the University of Florida. The grant, awarded on June 10, 2025, will support research to investigate lipid-gene molecular profiles in septic acute respiratory distress syndrome (ARDS) patients. The key goals are to: 1) identify novel septic ARDS phenotypes based on lipidomic and transcriptomic profiles, and 2) discover...
This Project Grant award of $462,000.00 from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) supports research to investigate how the human microbiome influences the immune response and survival outcomes in sepsis. The key objectives are to: Elucidate the underlying mechanisms by which the microbiome primes and regulates neutrophil function in healthy individuals. Determine the effects of microbiome-mediated neutrophil priming on...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a Project Grant under CFDA 93.855 - Allergy and Infectious Diseases Research to the University of Maryland, Baltimore (UMB) for $684,206 beginning on May 21, 2025. The objective of this R01 research project is to develop a nanoparticle-based immunotherapy to address the complex immune dysregulation in sepsis, a life-threatening condition. Key activities include evaluating the immunomodulatory properties of the...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) will provide $721,728 to the Regents of the University of Michigan to support research on the impact of persistent viral infections on the outcomes and immunomodulatory therapy responses of pediatric patients with sepsis. The research aims to define virus status as a determinant of sepsis phenotype and clinical...
The National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded a $569,210 Project Grant to the University of Colorado Boulder. The five-year grant, effective February 1, 2025, supports research to structurally and functionally characterize three proteins responsible for antimicrobial resistance, screen for probes to define inhibitory strategies, and develop a platform to quantitatively test the impact of target...
This federal Project Grant award of $578,093 from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 Allergy and Infectious Diseases Research) supports research to elucidate the structure and function of a novel damage-associated molecular pattern (DAMP) receptor, CLEC17A, in humans and its murine counterpart CD209f/g. The research aims to determine how these DAMP receptors on innate immune cells sense and respond to the release of the DAMP ligand GAPDH from injured cells,...